$117.570
+5.926 (+5.04%)Zum Schluss
MNPR im Vergleich zur Peergroup
In the context of the broader market, MNPR competes directly with industry leaders such as AURA and NGNE. With a market capitalization of $789.15M, it holds a leading position in the sector. When comparing efficiency, MNPR's gross margin of N/A stands against AURA's N/A and NGNE's N/A. Such benchmarking helps identify whether Monopar Therapeutics Inc. is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Monopar Therapeutics Inc
The company has faced significant net losses, with Q2 2026 net income at -5,313,300 USD, but it has shown a positive EPS of 0.62 in Q2 2026, indicating potential recovery.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.